Press release
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers
Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease
About this update from Natera, Inc.
[{"type":"text","content":"Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time was strongly associated with disease recurrence and poor prognosis\nAUSTIN, Texas, Dec. 9, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology highlighting the clinical utility of its personalized and tumor-informed molecular residual disease test, Signatera™, for postoperative risk stratification and prediction of recurrence in patients with stage I-III esophageal and gastric cancers (EGCs). The full study can be found here.\n\n \n \n \n \n \n \n\n \nEGCs are the sixth most common cancers worldwide,1 affecting approximately 47,000 new patients per year in the U.S.2 In patients with localized disease, despite treatment with curative-intent therapy, over 50% recur within three years.3-5 Today, clinical practice guidelines support either adjuvant therapy or observation post surgery, so there is a strong unmet need for better risk stratification tools to help inform these risk-based management decisions. In addition, due to the high rate of recurrence, guidelines recommend frequent monitoring for recurrence with imaging, endoscopic evaluation or tumor markers.6\nThis real-world study, one of the largest reported EGC studies to date, included 943 plasma samples collected from 295 patients across more than 70 institutions. The primary analysis focused on the 212 patients with stage I-III disease. Signatera ctDNA status was evaluated at diagnosis (prior to neoadjuvant treatment), post surgery and then serially during routine surveillance, with median clinical followup of 417 days.\n Key takeaways from the study include:\nPre-treatment: ctDNA was detectable in 96% (23/24) of patients with preoperative samples.Post surgery (within 16 weeks): ctDNA was detected post-surgically in 23.5% (16/68) of patients. ctDNA-positive patients experienced a higher rate of recurrence (81.2%) in comparison to ctDNA-negative patients (13.5%). ctDNA-positive patients experienced inferior RFS (HR: 10.7, 95% CI: 4.3-29.3, p","length":3183,"tagName":"div"}]